Age (mean ± std) |
16.85 (2.06) |
17.84 (2.11) |
(range) |
14-20 |
14-21 |
Gender: % female (n) |
15% (3)* |
47.36% (9)* |
Race: percent (n) |
|
|
% Caucasian |
50% (10) |
42.11% (8) |
% African American |
10% (2) |
5.2% (1) |
% Asian American/Pacific Islander |
15 %(3) |
10.5% (2) |
% Latino/Hispanic |
20% (4) |
10.5% (2) |
% Other |
5% (1) |
44.4% (4) |
Primary SIPS diagnosis: percent (n) |
|
|
Brief Intermittent Psychotic (BIPS) |
20% (4) |
|
Attenuated Positive Symptoms (APS) |
75% (15) |
|
Genetic Risk & Deterioration (GRD) |
5% (1) |
|
Medication Status (n)
|
|
|
Current atypical antipsychotic |
4 |
|
Current SSRI/SNRI |
7 |
|
Current mood stabilizer |
2 |
|
Current psychostimulant |
2 |
|
Current Other (cogentin, abilify, klonopin) |
3 |
|
No current medication |
10 |
|
One current medication |
5 |
|
Two current medications |
4 |
|
Three current medications |
0 |
|
Four current medications |
1 |
|